Although cures for age-related macular degeneration are elusive, the case for prevention through nutrition looks strong and ...

Key trends include advanced multicolor laser adoption and increased outpatient treatments. Challenges include reimbursement issues and competition from alternative therapies. Leading players like ...

Porton Advanced, a leading contract development and manufacturing organization (CDMO) specializing in advanced therapy ...

The global ophthalmic products market is projected to grow at a CAGR of 5-7% over the next 5 years. Rising cases of vision ...

Lupin will manufacture biosimilar ranibizumab while SteinCares handles registration and marketing in Latin America, excluding ...

Dry age-related macular degeneration (AMD ... While none are yet approved as of 2025, several candidates are in advanced stages of development with fast-track or regenerative medicine advanced ...

StainCares added that partnership plans to enhance its biosimilar portfolio and back cost-effective healthcare in Latin ...

Lupin partners with SteinCares to commercialize Ranibizumab in Latin America, aiming to improve retinal care access.

Lupin has signed an agreement with SteinCares for the commercialization of biosimilar ranibizumab in Latin America, excluding ...

Lupin has entered into a licence agreement with SteinCares for commercialisation of biosimilar ranibizumab across Latin ...